FDA Grants Olaparib Orphan Drug Designation for Pancreatic Cancer

October 16, 2018 – The FDA has granted Olaparib an orphan drug designation for the treatment of patients with pancreatic cancer, according to AstraZeneca and Merck, the developers of the PARP inhibitor. “The FDA granting orphan drug designation is a positive step for patients with pancreatic cancer and continues to reinforce the importance of our collaboration in bringing Olaparib to more patients in need,” said Roy Baynes, senior vice president and … (leggi tutto)